Skip to main content
Premium Trial:

Request an Annual Quote

BioTrove Raises $10.9M in Financing

NEW YORK, Jan. 29 (GenomeWeb News) - BioTrove said today it has raised $10.9 million in financing to develop its Living Chip technology and assays.


Investors in the round include Catalyst Health and Technology Partners, CB Health Ventures, Zero Stage Capital, and BioFrontier Partners.


The company, based in Woburn, Mass., is aiming its Living Chip technology, a nano-fluidics platform, at analysis of genomic, proteomic, cellular, and other biochemical samples. It also is developing a mass spectrometry service, Momentum Assay Development and Screening, for microliter-scale assays and screening.


The company also said it has appointed to its board of directors Ben Bronstein, amanaging director at Zero Stage Capital.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.